Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 11, 2026

Insilico and CMS launch drug discovery collaborations for CNS diseases

Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases.

The collaboration will combine Insilico Medicine’s technologies for small-molecule design, candidate molecules screening, and target identification. Credit: tilialucida / Shutterstock.com.